Biomarin Pharmaceutical (BMRN) Superinvestor holders
22 of the superinvestors we track hold Biomarin Pharmaceutical (BMRN) in their latest 13F filings, $2.6B in total.
Summary
The largest holder is Dodge & Cox, with $849M, 0.4% of the portfolio.
In their latest quarter: 3 opened a new position, 7 added, 10 trimmed.
Who holds it
Each investor's latest 13F filing, largest stake first. What a 13F shows.
| Investor | Last change | Shares | Value | % of portfolio | Filed for |
|---|---|---|---|---|---|
| Dodge & Cox | Added | 14,844,930 | $849M | 0.4% | Q2 2026 |
| PRIMECAP Management PRIMECAP Management Co |
Trimmed | 14,190,183 | $812M | 0.5% | Q2 2026 |
| Andreas Halvorsen Viking Global Investors |
Added | 7,616,563 | $436M | 1.2% | Q2 2026 |
| Cliff Asness AQR Capital Management |
Trimmed | 5,699,541 | $323M | 0.1% | Q2 2026 |
| Josef Lakonishok LSV Asset Management |
Trimmed | 712,100 | $43M | 0.1% | Q3 2026 |
| Aziz Hamzaogullari Loomis Sayles & Co |
Trimmed | 713,657 | $41M | 0.1% | Q2 2026 |
| Jim Simons Renaissance Technologies |
Trimmed | 451,871 | $26M | 0.0% | Q2 2026 |
| Hotchkis & Wiley Hotchkis & Wiley Capital Management |
New position | 447,200 | $26M | 0.1% | Q2 2026 |
| Man Group Man Group plc |
Added | 367,981 | $21M | 0.0% | Q2 2026 |
| Ray Dalio Bridgewater Associates |
Added | 274,911 | $16M | 0.1% | Q2 2026 |
| Mark Donovan Boston Partners |
New position | 153,446 | $9M | 0.0% | Q2 2026 |
| Paul Marshall Marshall Wace |
New position | 97,300 | $6M | 0.0% | Q2 2026 |
| David Shaw D. E. Shaw & Co. |
Trimmed | 92,214 | $5M | 0.0% | Q2 2026 |
| Robert Torray Torray Investment Partners |
Trimmed | 73,615 | $4M | 0.6% | Q3 2026 |
| Thornburg Thornburg Investment Management |
Added | 43,061 | $2M | 0.0% | Q2 2026 |
| Two Sigma Two Sigma Investments |
Trimmed | 28,775 | $2M | 0.0% | Q2 2026 |
| Joel Greenblatt Gotham Asset Management |
Trimmed | 28,641 | $2M | 0.0% | Q2 2026 |
| WCM Investment Management | Added | 22,930 | $1M | 0.0% | Q2 2026 |
| Mario Gabelli GAMCO Investors |
Trimmed | 13,000 | $743,860 | 0.0% | Q2 2026 |
| Brandon Haley Holocene Advisors |
Held | 11,679 | $668,272 | 0.0% | Q2 2026 |
| Alan Breed Edgewood Management |
Held | 10,000 | $572,200 | 0.0% | Q2 2026 |
| Ensign Peak Ensign Peak Advisors |
Added | 9,718 | $556,064 | 0.0% | Q2 2026 |
Holders by quarter
| Quarter | Superinvestors holding it |
|---|---|
| Q2 2026 | 24 |
| Q1 2026 | 24 |
| Q4 2025 | 28 |
| Q3 2025 | 27 |
| Q2 2025 | 29 |
| Q1 2025 | 30 |
| Q4 2024 | 27 |
| Q3 2024 | 30 |
Questions about Biomarin Pharmaceutical
Which superinvestors own Biomarin Pharmaceutical?
22 of the superinvestors we track hold Biomarin Pharmaceutical (BMRN) in their latest 13F filings, $2.6B in total. Dodge & Cox, PRIMECAP Management, Andreas Halvorsen, Cliff Asness, Josef Lakonishok, Aziz Hamzaogullari.
Who is the largest superinvestor holder of BMRN?
The largest holder is Dodge & Cox, with $849M, 0.4% of the portfolio.
From Biomarin Pharmaceutical's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.